[
  {
    "ts": "2025-10-06T21:50:02+00:00",
    "headline": "Amgen (AMGN) Stock Sinks As Market Gains: Here's Why",
    "summary": "Amgen (AMGN) reached $294.12 at the closing of the latest trading day, reflecting a -1.27% change compared to its last close.",
    "url": "https://finance.yahoo.com/news/amgen-amgn-stock-sinks-market-215002330.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "27953a93-4795-3fa9-a95b-dac4e026672f",
      "content": {
        "id": "27953a93-4795-3fa9-a95b-dac4e026672f",
        "contentType": "STORY",
        "title": "Amgen (AMGN) Stock Sinks As Market Gains: Here's Why",
        "description": "",
        "summary": "Amgen (AMGN) reached $294.12 at the closing of the latest trading day, reflecting a -1.27% change compared to its last close.",
        "pubDate": "2025-10-06T21:50:02Z",
        "displayTime": "2025-10-06T21:50:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/105b2acef7bf0873f24b78932b1fdc3c",
          "originalWidth": 900,
          "originalHeight": 675,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5VYVrk.dAWOtAbYePjBVnw--~B/aD02NzU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/105b2acef7bf0873f24b78932b1fdc3c.cf.webp",
              "width": 900,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bx6KQdkgJ6y2nL6XqljE4w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/105b2acef7bf0873f24b78932b1fdc3c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgen-amgn-stock-sinks-market-215002330.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-amgn-stock-sinks-market-215002330.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^IXIC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-06T19:23:02+00:00",
    "headline": "Amgen Slashes Drug Price After Trump Threat--Repatha Now 60% Cheaper Online",
    "summary": "Biotech giant rushes to comply with Trump's drug price crackdown, joins Pfizer in avoiding tariff backlash",
    "url": "https://finance.yahoo.com/news/amgen-slashes-drug-price-trump-192302194.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "cedf5525-b79d-3307-bdff-ae1d87c84435",
      "content": {
        "id": "cedf5525-b79d-3307-bdff-ae1d87c84435",
        "contentType": "STORY",
        "title": "Amgen Slashes Drug Price After Trump Threat--Repatha Now 60% Cheaper Online",
        "description": "",
        "summary": "Biotech giant rushes to comply with Trump's drug price crackdown, joins Pfizer in avoiding tariff backlash",
        "pubDate": "2025-10-06T19:23:02Z",
        "displayTime": "2025-10-06T19:23:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/1452eab9fb2716c0d09851a7f122cb36",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/e5pRiGxxtJQV4VeecSohcw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/1452eab9fb2716c0d09851a7f122cb36.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GL9j9DM9uZjUb6dSDdVF.g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/1452eab9fb2716c0d09851a7f122cb36.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgen-slashes-drug-price-trump-192302194.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-slashes-drug-price-trump-192302194.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-06T16:38:50+00:00",
    "headline": "Amgen to sell cholesterol drug at 60% discount to cash-paying US patients",
    "summary": "By Deena Beasley LOS ANGELES (Reuters) -Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol-lowering medication Repatha at a discounted cash price, becoming the latest",
    "url": "https://finance.yahoo.com/news/amgen-sell-cholesterol-drug-60-163850903.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "66b94ec6-f472-3483-af60-26e0964e7869",
      "content": {
        "id": "66b94ec6-f472-3483-af60-26e0964e7869",
        "contentType": "STORY",
        "title": "Amgen to sell cholesterol drug at 60% discount to cash-paying US patients",
        "description": "",
        "summary": "By Deena Beasley LOS ANGELES (Reuters) -Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol-lowering medication Repatha at a discounted cash price, becoming the latest",
        "pubDate": "2025-10-06T16:38:50Z",
        "displayTime": "2025-10-06T16:38:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/3e2f195d48969f82d24dfa7e8895e13e",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UFmvtkQ473gT3wQ8cTrk3A--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/3e2f195d48969f82d24dfa7e8895e13e.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nw4ZRL943_CY0HhGLeAqNg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/3e2f195d48969f82d24dfa7e8895e13e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgen-sell-cholesterol-drug-60-163850903.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-sell-cholesterol-drug-60-163850903.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-06T15:09:00+00:00",
    "headline": "Amgen Lowers Cholesterol-Medication Price After Trump Call for Price Cuts",
    "summary": "The biotechnology company said that it has launched AmgenNow, a new direct-to-patient program, starting with its drug Repatha.",
    "url": "https://www.wsj.com/health/pharma/amgen-lowers-cholesterol-medication-price-after-trump-call-for-price-cuts-8fa2071d?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "6180cebc-795b-3d33-a42e-782c8816e496",
      "content": {
        "id": "6180cebc-795b-3d33-a42e-782c8816e496",
        "contentType": "STORY",
        "title": "Amgen Lowers Cholesterol-Medication Price After Trump Call for Price Cuts",
        "description": "",
        "summary": "The biotechnology company said that it has launched AmgenNow, a new direct-to-patient program, starting with its drug Repatha.",
        "pubDate": "2025-10-06T15:09:00Z",
        "displayTime": "2025-10-06T15:09:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/6180cebc-795b-3d33-a42e-782c8816e496/amgen-lowers.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/8e8b630efc40455698e0219a127edaca",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NPrpvzIdATQbVZSAyjV19w--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/8e8b630efc40455698e0219a127edaca.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OoNoQQbeTRcYIwAQBG8nqA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/8e8b630efc40455698e0219a127edaca.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/amgen-lowers-cholesterol-medication-price-after-trump-call-for-price-cuts-8fa2071d?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-06T13:53:00+00:00",
    "headline": "Bullous Pemphigoid Market Analysis and Forecast Report 2025-2035",
    "summary": "Emerging technologies in diagnostics and telemedicine are transforming patient management, although high costs and variable patient responses remain barriers. With growing investments in dermatological research, demand is driven by the aging population and advanced diagnostic techniques. Key market players include Sanofi, Regeneron, and Amgen.Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The \"Bullous Pemphigoid Market - A Global and Regional Analysis: Focus on Therapy Type and Region - Analysis and",
    "url": "https://finance.yahoo.com/news/bullous-pemphigoid-market-analysis-forecast-135300701.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "2f38db95-b203-3af2-8694-23d2e9c2c4e0",
      "content": {
        "id": "2f38db95-b203-3af2-8694-23d2e9c2c4e0",
        "contentType": "STORY",
        "title": "Bullous Pemphigoid Market Analysis and Forecast Report 2025-2035",
        "description": "",
        "summary": "Emerging technologies in diagnostics and telemedicine are transforming patient management, although high costs and variable patient responses remain barriers. With growing investments in dermatological research, demand is driven by the aging population and advanced diagnostic techniques. Key market players include Sanofi, Regeneron, and Amgen.Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The \"Bullous Pemphigoid Market - A Global and Regional Analysis: Focus on Therapy Type and Region - Analysis and",
        "pubDate": "2025-10-06T13:53:00Z",
        "displayTime": "2025-10-06T13:53:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bullous-pemphigoid-market-analysis-forecast-135300701.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bullous-pemphigoid-market-analysis-forecast-135300701.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SAN.PA"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-06T13:40:02+00:00",
    "headline": "Here's Why Amgen (AMGN) is a Strong Value Stock",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finance.yahoo.com/news/heres-why-amgen-amgn-strong-134002909.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "9de81811-45cc-33e4-be08-9ffe6af544b3",
      "content": {
        "id": "9de81811-45cc-33e4-be08-9ffe6af544b3",
        "contentType": "STORY",
        "title": "Here's Why Amgen (AMGN) is a Strong Value Stock",
        "description": "",
        "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
        "pubDate": "2025-10-06T13:40:02Z",
        "displayTime": "2025-10-06T13:40:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/7ea641b46fe75c0a913349e5e610d6a2",
          "originalWidth": 900,
          "originalHeight": 625,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3cJ1IMl6d4bpPpYAD.IsQw--~B/aD02MjU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7ea641b46fe75c0a913349e5e610d6a2.cf.webp",
              "width": 900,
              "height": 625,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PlkanZFCHurVHg.4Kx4ifw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7ea641b46fe75c0a913349e5e610d6a2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-why-amgen-amgn-strong-134002909.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-why-amgen-amgn-strong-134002909.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-06T13:15:00+00:00",
    "headline": "GoodRx Expands Affordable Access to Repatha® with Nearly 60% Savings",
    "summary": "SANTA MONICA, Calif., October 06, 2025--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® (evolocumab), a cholesterol-lowering therapy, at a significantly reduced cash price. Starting today, patients can use GoodRx to access Repatha for $239 at more than 70,000 pharmacies nationwide, a savings of nearly 60% off the retail pharmacy list price.",
    "url": "https://finance.yahoo.com/news/goodrx-expands-affordable-access-repatha-131500931.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "38e113e6-3fb3-35ac-9156-abe75ee426cb",
      "content": {
        "id": "38e113e6-3fb3-35ac-9156-abe75ee426cb",
        "contentType": "STORY",
        "title": "GoodRx Expands Affordable Access to Repatha® with Nearly 60% Savings",
        "description": "",
        "summary": "SANTA MONICA, Calif., October 06, 2025--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® (evolocumab), a cholesterol-lowering therapy, at a significantly reduced cash price. Starting today, patients can use GoodRx to access Repatha for $239 at more than 70,000 pharmacies nationwide, a savings of nearly 60% off the retail pharmacy list price.",
        "pubDate": "2025-10-06T13:15:00Z",
        "displayTime": "2025-10-06T13:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/4ba582555963f6ebd27333a510a38d58",
          "originalWidth": 480,
          "originalHeight": 389,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/d48kJW0oV3bVyV9V018thg--~B/aD0zODk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4ba582555963f6ebd27333a510a38d58.cf.webp",
              "width": 480,
              "height": 389,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XloFhWpC.zBgntGLEyDy_Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4ba582555963f6ebd27333a510a38d58.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/goodrx-expands-affordable-access-repatha-131500931.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/goodrx-expands-affordable-access-repatha-131500931.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "GDRX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-06T13:00:10+00:00",
    "headline": "Is There An Opportunity With Amgen Inc.'s (NASDAQ:AMGN) 49% Undervaluation?",
    "summary": "Key Insights The projected fair value for Amgen is US$586 based on 2 Stage Free Cash Flow to Equity Current share price...",
    "url": "https://finance.yahoo.com/news/opportunity-amgen-inc-nasdaq-amgn-130010764.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "b47039c7-cfde-3dea-b137-2faf72c6cba6",
      "content": {
        "id": "b47039c7-cfde-3dea-b137-2faf72c6cba6",
        "contentType": "STORY",
        "title": "Is There An Opportunity With Amgen Inc.'s (NASDAQ:AMGN) 49% Undervaluation?",
        "description": "",
        "summary": "Key Insights The projected fair value for Amgen is US$586 based on 2 Stage Free Cash Flow to Equity Current share price...",
        "pubDate": "2025-10-06T13:00:10Z",
        "displayTime": "2025-10-06T13:00:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ACuIXYrNeojUXbAJFhnPIg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B7CQJIEa.2c0sQ0XIU66pg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/opportunity-amgen-inc-nasdaq-amgn-130010764.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/opportunity-amgen-inc-nasdaq-amgn-130010764.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]